Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$14.78
-0.18-1.20%
At close: -
$14.78
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Elanco Animal Health Analyst Ratings and Price Targets | NYSE:ELAN | Benzinga
Elanco Animal Health Inc has a consensus price target of $16 based on the ratings of 12 analysts. The high is $20 issued by Morgan Stanley on November 15, 2022. The low is $9 issued by Goldman Sachs on April 25, 2023. The 3 most-recent analyst ratings were released by Leerink Partners, Stifel, and Stifel on July 17, 2025, July 2, 2025, and May 19, 2025, respectively. With an average price target of $17 between Leerink Partners, Stifel, and Stifel, there's an implied 15.02% upside for Elanco Animal Health Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Leerink Partners
Stifel
Piper Sandler
UBS
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for Elanco Animal Health
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
07/17/2025 | 21.79% | Leerink Partners | → $18 | Upgrade | Market Perform → Outperform | |||
07/02/2025 | 15.02% | Stifel | $16 → $17 | Maintains | Buy | |||
06/26/2025 | — | William Blair | — | Upgrade | Market Perform → Outperform | |||
05/19/2025 | 8.25% | Stifel | $15 → $16 | Maintains | Buy | |||
05/08/2025 | 1.49% | Stifel | $13 → $15 | Maintains | Buy | |||
04/14/2025 | -12.04% | Stifel | $15 → $13 | Maintains | Buy | |||
03/06/2025 | -18.81% | Piper Sandler | $16 → $12 | Maintains | Neutral | |||
02/26/2025 | 15.02% | UBS | $18 → $17 | Maintains | Buy | |||
02/26/2025 | -12.04% | Morgan Stanley | $14 → $13 | Maintains | Equal-Weight | |||
02/26/2025 | 1.49% | Stifel | $16 → $15 | Maintains | Buy | |||
02/26/2025 | 28.55% | Barclays | $20 → $19 | Maintains | Overweight | |||
02/21/2025 | 8.25% | Stifel | $18 → $16 | Maintains | Buy | |||
01/29/2025 | -5.28% | Morgan Stanley | $15 → $14 | Maintains | Equal-Weight | |||
01/07/2025 | 21.79% | Stifel | $20 → $18 | Maintains | Buy | |||
12/09/2024 | 21.79% | UBS | → $18 | Initiates | → Buy | |||
12/02/2024 | -5.28% | Leerink Partners | → $14 | Initiates | → Market Perform | |||
11/08/2024 | 35.32% | Barclays | $19 → $20 | Maintains | Overweight | |||
10/28/2024 | 28.55% | Barclays | $22 → $19 | Maintains | Overweight | |||
09/23/2024 | 48.85% | Barclays | $21 → $22 | Maintains | Overweight | |||
09/19/2024 | 35.32% | Stifel | $20 → $20 | Reiterates | Buy → Buy | |||
09/19/2024 | 1.49% | Morgan Stanley | $17 → $15 | Downgrade | Overweight → Equal-Weight | |||
07/01/2024 | 8.25% | Piper Sandler | $19 → $16 | Maintains | Neutral | |||
06/28/2024 | 42.08% | Barclays | $23 → $21 | Maintains | Overweight | |||
05/13/2024 | 28.55% | Piper Sandler | $18 → $19 | Reiterates | Neutral → Neutral | |||
05/09/2024 | 55.62% | Barclays | $19 → $23 | Maintains | Overweight | |||
03/12/2024 | 21.79% | Piper Sandler | $12 → $18 | Reiterates | Neutral → Neutral | |||
02/27/2024 | -5.28% | Goldman Sachs | $12.5 → $14 | Maintains | Sell | |||
02/27/2024 | 15.02% | Morgan Stanley | $16 → $17 | Maintains | Overweight | |||
02/27/2024 | 28.55% | Barclays | $18 → $19 | Maintains | Overweight | |||
01/17/2024 | -15.43% | Goldman Sachs | $10 → $12.5 | Maintains | Sell | |||
01/05/2024 | 35.32% | Stifel | $13 → $20 | Upgrade | Hold → Buy | |||
12/19/2023 | 15.02% | Jefferies | → $17 | Initiates | → Buy | |||
12/15/2023 | 8.25% | Morgan Stanley | → $16 | Upgrade | Equal-Weight → Overweight | |||
12/07/2023 | -12.04% | Stifel | $12 → $13 | Maintains | Hold | |||
11/13/2023 | -18.81% | Piper Sandler | $11 → $12 | Maintains | Neutral | |||
11/08/2023 | 8.25% | Morgan Stanley | $17 → $16 | Maintains | Equal-Weight | |||
10/30/2023 | -18.81% | Stifel | $13 → $12 | Maintains | Hold | |||
08/14/2023 | -12.04% | Piper Sandler | $9 → $13 | Maintains | Neutral | |||
08/09/2023 | -35.72% | Goldman Sachs | $8.5 → $9.5 | Maintains | Sell | |||
08/08/2023 | -35.72% | Goldman Sachs | $8.5 → $9.5 | Maintains | Sell | |||
04/26/2023 | -39.11% | Goldman Sachs | $10.5 → $9 | Maintains | Sell | |||
04/25/2023 | -39.11% | Goldman Sachs | $10.5 → $9 | Maintains | Sell | |||
04/20/2023 | -5.28% | Barclays | → $14 | Upgrade | Equal-Weight → Overweight | |||
02/22/2023 | -5.28% | Barclays | $18 → $14 | Maintains | Equal-Weight | |||
01/30/2023 | 28.55% | Morgan Stanley | $20 → $19 | Maintains | Equal-Weight | |||
11/15/2022 | 35.32% | Morgan Stanley | $21 → $20 | Maintains | Equal-Weight | |||
11/14/2022 | 1.49% | Piper Sandler | $21 → $15 | Maintains | Neutral | |||
11/09/2022 | -18.81% | Goldman Sachs | $19 → $12 | Maintains | Sell | |||
10/17/2022 | 35.32% | JP Morgan | $24 → $20 | Maintains | Neutral | |||
10/07/2022 | 42.08% | Morgan Stanley | $22 → $21 | Maintains | Equal-Weight | |||
09/12/2022 | 21.79% | Barclays | $32 → $18 | Maintains | Equal-Weight | |||
08/18/2022 | 48.85% | Morgan Stanley | $37 → $22 | Downgrade | Overweight → Equal-Weight | |||
08/17/2022 | 42.08% | Piper Sandler | $22 → $21 | Maintains | Neutral | |||
08/16/2022 | — | JP Morgan | — | Downgrade | Overweight → Neutral | |||
07/21/2022 | 28.55% | Goldman Sachs | $32 → $19 | Downgrade | Buy → Sell |
FAQ
What is the target price for Elanco Animal Health (ELAN) stock?
The latest price target for Elanco Animal Health (NYSE:ELAN) was reported by Leerink Partners on July 17, 2025. The analyst firm set a price target for $18.00 expecting ELAN to rise to within 12 months (a possible 21.79% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Elanco Animal Health (ELAN)?
The latest analyst rating for Elanco Animal Health (NYSE:ELAN) was provided by Leerink Partners, and Elanco Animal Health upgraded their outperform rating.
When was the last upgrade for Elanco Animal Health (ELAN)?
The last upgrade for Elanco Animal Health Inc happened on July 17, 2025 when Leerink Partners raised their price target to $18. Leerink Partners previously had a market perform for Elanco Animal Health Inc.
When was the last downgrade for Elanco Animal Health (ELAN)?
The last downgrade for Elanco Animal Health Inc happened on September 19, 2024 when Morgan Stanley changed their price target from $17 to $15 for Elanco Animal Health Inc.
When is the next analyst rating going to be posted or updated for Elanco Animal Health (ELAN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Elanco Animal Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Elanco Animal Health was filed on July 17, 2025 so you should expect the next rating to be made available sometime around July 17, 2026.
Is the Analyst Rating Elanco Animal Health (ELAN) correct?
While ratings are subjective and will change, the latest Elanco Animal Health (ELAN) rating was a upgraded with a price target of $0.00 to $18.00. The current price Elanco Animal Health (ELAN) is trading at is $14.78, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
